Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 351 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Invasive Carcinoma of the Breast Clear all
Recruiting Not applicable Interventional

Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery

NCT05327608
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
Interventions
Short-Term Fasting, Chemotherapy, Biospecimen Collection, Questionnaire Administration
Other · Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Cherry Hill, New Jersey • Sewell, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 28, 2026, 6:39 PM EDT
Recruiting No phase listed Observational

Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer

NCT06666439
View directory record Official record
Conditions
Metastatic Invasive Lobular Carcinoma (mILC)
Interventions
circulating tumor DNA (ctDNA)
Diagnostic Test
Lead sponsor
Julia Foldi
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 28, 2026, 6:39 PM EDT
Terminated Phase 2 Interventional Results available

A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant

NCT02540330
View directory record Official record
Conditions
Female Breast Carcinoma, Female Ductal Carcinoma In Situ
Interventions
Fulvestrant
Drug
Lead sponsor
Atossa Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Sep 28, 2026, 6:39 PM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation

NCT01856543
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Eucerin, Mometasone Furoate 0.1%
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Sep 28, 2026, 6:39 PM EDT
Completed Phase 2 Interventional

Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery

NCT03188393
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Biopsy of Breast
Procedure
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
377
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 256 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 28, 2026, 6:39 PM EDT
Completed Phase 2 Interventional

Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

NCT00146601
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Boston, Massachusetts • Lowell, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Sep 28, 2026, 6:39 PM EDT
Terminated Phase 1 Interventional

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

NCT03128619
View directory record Official record
Conditions
Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Postmenopausal, Progesterone Receptor Positive, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Biopsy of Breast, Copanlisib, Laboratory Biomarker Analysis, Letrozole, Palbociclib, Pharmacological Study
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 28, 2026, 6:39 PM EDT
Suspended Phase 3 Interventional

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial

NCT06671912
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Anastrozole, Letrozole, Exemestane, Tamoxifen, Mammogram, Magnetic Resonance Imaging, Dual X-ray Absorptiometry, Biospecimen Collection, Questionnaire Administration
Drug · Procedure · Biological + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
728
States / cities
Anchorage, Alaska • Gilbert, Arizona • Goodyear, Arizona + 559 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 28, 2026, 6:39 PM EDT
Completed Early Phase 1 Interventional

Broccoli Sprout Extract in Treating Patients With Breast Cancer

NCT01753908
View directory record Official record
Conditions
Ductal Breast Carcinoma, Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative, Estrogen Receptor Positive, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Postmenopausal, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
Broccoli Sprout Extract, Laboratory Biomarker Analysis, Pharmacological Study, Placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 28, 2026, 6:39 PM EDT
Terminated Phase 1 Interventional

Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma

NCT01816555
View directory record Official record
Conditions
Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II
Interventions
Vitamin D
Dietary Supplement
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Sep 28, 2026, 6:39 PM EDT
Terminated Phase 2 Interventional Results available

Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery

NCT01754519
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Cribriform Breast Carcinoma, Invasive Ductal Carcinoma, Not Otherwise Specified, Lobular Breast Carcinoma In Situ, Mucinous Breast Carcinoma, Papillary Breast Carcinoma, Progesterone Receptor Positive, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Tubular Breast Carcinoma
Interventions
Therapeutic Conventional Surgery, Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Procedure · Radiation · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 28, 2026, 6:39 PM EDT
Recruiting Phase 2 Interventional

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

NCT07076485
View directory record Official record
Conditions
Breast Cancer
Interventions
Ultrahypofractionated Radiation, Moderately Hypofractionated Radiation
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Loveland, Colorado • Jacksonville, Florida • Voorhees Township, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 28, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

NCT03323658
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma
Interventions
Bexarotene, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Sep 28, 2026, 6:39 PM EDT
Completed Phase 2 Interventional Results available

Endocrine Response in Women With Invasive Lobular Breast Cancer

NCT02206984
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen, Anastrozole, Fulvestrant
Drug
Lead sponsor
Priscilla McAuliffe
Other
Eligibility
Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 28, 2026, 6:39 PM EDT
Active, not recruiting Phase 2 Interventional

Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer

NCT01334021
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Biopsy, Conventional Surgery, Genetic Testing
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 28, 2026, 6:39 PM EDT
Completed Phase 1 Interventional

Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer

NCT03958721
View directory record Official record
Conditions
Resistant Breast Cancer, Non-metastatic Invasive Breast Cancer
Interventions
Capecitabine, Radiotherapy
Drug · Radiation
Lead sponsor
A Bapsi Chakravarthy, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 26, 2023 · Synced Sep 28, 2026, 6:39 PM EDT
Completed Early Phase 1 Interventional

Radiation Therapy in Treating Women With Invasive Breast Cancer

NCT00301041
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis, adjuvant therapy, radiation therapy
Other · Procedure · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Sep 28, 2026, 6:39 PM EDT
Not listed Phase 2 Interventional Results available

Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer

NCT00723294
View directory record Official record
Conditions
Breast Cancer
Interventions
cryosurgery, therapeutic conventional surgery
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
16
States / cities
Burbank, California • Bridgeport, Connecticut • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 28, 2026, 6:39 PM EDT
Completed No phase listed Observational Results available

Breast Cancer Genome Guided Therapy Study (BEAUTY)

NCT02022202
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 28, 2026, 6:39 PM EDT
Completed Not applicable Interventional

Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer

NCT04022772
View directory record Official record
Conditions
Breast Carcinoma, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Recurrent Breast Carcinoma
Interventions
Best Practice, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration, Supportive Care
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 28, 2026, 6:39 PM EDT
Terminated Phase 2 Interventional Results available

Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy

NCT01388777
View directory record Official record
Conditions
Breast Cancer
Interventions
Visica 2™ Treatment System, Cryoablation, Surgical Resection
Device · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 28, 2026, 6:39 PM EDT
Terminated Phase 2 Interventional Results available

ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

NCT00496379
View directory record Official record
Conditions
Breast Cancer, CNS Disease
Interventions
ZK219477
Drug
Lead sponsor
Nancy Lin, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 28, 2026, 6:39 PM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00438659
View directory record Official record
Conditions
Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
Interventions
mometasone furoate, placebo
Drug · Other
Lead sponsor
North Central Cancer Treatment Group
Network
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
189
States / cities
Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Sep 28, 2026, 6:39 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

NCT05334069
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma, Ann Arbor Stage III Lymphoma, Ann Arbor Stage IV Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Gastroesophageal Junction Adenocarcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Breast Carcinoma, Kidney Carcinoma, Malignant Hepatobiliary Neoplasm, Malignant Solid Neoplasm, Melanoma, Muscle-Invasive Bladder Carcinoma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma, RISS Stage III Plasma Cell Myeloma, Sarcoma, Stage I Bladder Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Esophageal Cancer AJCC V7, Stage I Gastric Cancer AJCC V7, Stage I Lung Cancer AJCC v7, Stage I Ovarian Cancer AJCC v6 and v7, Stage I Pancreatic Cancer AJCC v6 and v7, Stage I Prostate Cancer AJCC v7, Stage I Uterine Corpus Cancer AJCC v7, Stage II Bladder Cancer AJCC v6 and v7, Stage II Breast Cancer AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Esophageal Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage II Lung Cancer AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage II Prostate Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage III Bladder Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Bladder Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Lung Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Thyroid Gland Carcinoma
Interventions
Questionnaire Administration, Biospecimen Collection
Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
40 Years to 75 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
745
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 501 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 28, 2026, 6:39 PM EDT